In recent years, the use of injectable weight-loss medications, particularly GLP-1 drugs like Wegovy and Zepbound, has become increasingly widespread. However, a pertinent question arises regarding the consequences of ceasing these treatments. While anecdotal evidence largely points to significant weight regain following discontinuation, a study conducted by the Cleveland Clinic has unveiled more complex outcomes. This analysis examined nearly 8,000 individuals and aimed to dissect the experiences of those who stopped using these commonly prescribed medications.

Study Outcomes Diverge from Clinical Trials

The research findings, detailed in the journal Diabetes, Obesity and Metabolism, challenge previous assumptions drawn from clinical trials. Earlier studies indicated that many patients would regain over half of the weight they lost within 12 months after stopping treatment. However, the real-world experiences of patients have shown different results. As noted by Hamlet Gasoyan, the study’s lead author, many patients do not simply stop treatment but may switch to alternative therapies, thereby influencing weight regain outcomes.

Patient Experiences After Treatment Discontinuation

The study tracked 7,938 adults from Ohio and Florida who had ceased using semaglutide or tirzepatide within a time frame of three to twelve months. Prior to discontinuation, participants had achieved noteworthy weight loss: those using the drugs for obesity experienced an average reduction of 8.4% in their body weight, while those prescribed the medication for type 2 diabetes lost about 4.4%. A follow-up after one year revealed varied results. Patients seeking obesity treatment regained an average of only 0.5% of their weight, whereas those managing diabetes maintained slight weight loss.

Weight Management Options After Stopping Medication

Outcomes differed significantly among patients. More than half of the individuals treated for obesity did gain some weight, but 45% either maintained their weight or continued to lose. Among the diabetes patient group, over half exhibited stable or further weight loss. A notable aspect of the study was that many individuals sought alternative methods for weight management within the year following their medication cessation: 27% opted for different drugs, which included older obesity medications or a switch between semaglutide and tirzepatide, while 20% resumed their original treatment. Another 14% engaged in lifestyle counseling sessions with healthcare providers. Fewer than 1% chose to pursue metabolic or bariatric surgery.

Reasons for Stopping Medication

Cost has emerged as the primary motive for patients discontinuing the medications, followed closely by side effects. Insurance coverage has been pivotal in influencing whether individuals choose to restart therapy. Instead of fully abandoning their treatment plans, many have sought alternative options to maintain their weight management strategies. The data indicates a proactive approach among patients who either transitioned to other medications or turned to lifestyle modifications.

Long-term Perspective on Obesity Treatment

The results shed light on a progressive view toward obesity management—not as a single remedy, but as an ongoing need that may trigger multiple intervention types over time. The study advocates for the importance of sustained support for patients, illustrating that stopping medication is not synonymous with the end of treatment. Instead, this transition often leads to the exploration of diverse weight management methods. As the adoption of GLP-1 drugs continues to rise, these findings offer optimism: while the potential for weight regain exists, especially when patients remain actively engaged in their health care, it is not guaranteed.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share